Longeveron Inc.
General ticker "LGVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $11.1M (TTM average)
Longeveron Inc. does not follow the US Stock Market performance with the rate: -13.4%.
Estimated limits based on current volatility of 4.1%: low 1.40$, high 1.85$
Factors to consider:
- Total employees count: 37 (+48.0%) as of 2025
- Top business risk factors: Liquidity and credit risks, No approved products, History of losses, Regulatory and compliance, Clinical trial failure
- Current price 38.6% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.26$, 8.35$]
- 2026-12-31 to 2027-12-31 estimated range: [1.39$, 5.21$]
Financial Metrics affecting the LGVN estimates:
- Negative: with PPE of -1.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Inventory ratio change, % of -1.58 <= -1.30
- Negative: negative Net income
- Positive: -7.11 < Investing cash flow per share per price, % of -6.45
Short-term LGVN quotes
Long-term LGVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.71MM | $2.39MM | $1.20MM |
| Operating Expenses | $21.74MM | $18.91MM | $24.49MM |
| Operating Income | $-21.03MM | $-16.52MM | $-23.29MM |
| Non-Operating Income | $-0.38MM | $0.55MM | $0.58MM |
| R&D Expense | $9.07MM | $8.14MM | $12.04MM |
| Income(Loss) | $-21.41MM | $-15.97MM | $-22.70MM |
| Net Income(Loss)* | $-21.41MM | $-15.97MM | $-22.70MM |
| Stockholders Equity | $6.74MM | $21.89MM | $5.67MM |
| Assets | $12.08MM | $25.56MM | $10.26MM |
| Operating Cash Flow | $-19.00MM | $-13.87MM | $-18.64MM |
| Capital expenditure | $0.30MM | $0.99MM | $0.24MM |
| Investing Cash Flow | $8.19MM | $-0.64MM | $-0.59MM |
| Financing Cash Flow | $5.26MM | $28.79MM | $4.67MM |
| Earnings Per Share** | $-98.52 | $-10.73 | $-12.92 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.